Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ammeltz is a topical analgesic liniment formulated for the relief of musculoskeletal pain, including shoulder and neck pain, back pain, muscle aches, sprains, and strains. It is a multi-ingredient combination drug typically containing methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol. The drug exerts its therapeutic effect through a combination of mechanisms: methyl salicylate acts as a topical anti-inflammatory by inhibiting prostaglandin synthesis; menthol and camphor function as counterirritants that stimulate sensory receptors to create cooling and warming sensations, thereby masking pain; and chlorpheniramine maleate serves as a mild antihistamine to reduce local irritation. Originally developed by Kobayashi Pharmaceutical, Ammeltz is widely used in Asian markets and was approved for listing in China in 2011.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ammeltz.